Drug Profile
GS 986
Alternative Names: GS 9620 analogue; GS-986Latest Information Update: 09 Apr 2020
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Beth Israel Deaconess Medical Center; Gilead Sciences
- Class Pteridines; Pyrrolidines; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 24 Jul 2019 Pharmacodynamics data from preclinical studies in HIV infections were released by Gilead Sciences
- 28 Mar 2019 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
- 13 Feb 2017 Preclinical data in HIV-1 infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)